[{"id":"05673734-7805-481a-aece-aab9e02b28e6","acronym":"KEYNOTE-D17","url":"https://clinicaltrials.gov/study/NCT05479812","created_at":"2025-02-25T16:17:59.490Z","updated_at":"2025-02-25T16:17:59.490Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab (pembro) in Patients with Selected Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05479812 - KEYNOTE-D17","lead_sponsor":"Werewolf Therapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • WTX-124"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-12-27"}]